ACTOPLUS MET XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
May 2009
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTOPLUS MET XR is a fixed-dose combination oral tablet combining pioglitazone (thiazolidinedione) and metformin (biguanide) in extended-release formulation, approved in 2009 for type 2 diabetes. The mechanism of action involves improving insulin sensitivity via PPAR-gamma activation and reducing hepatic glucose production through AMP kinase activation. This adjunctive therapy targets patients inadequately controlled on monotherapy.
LOE Approaching3mo to LOE
Product faces imminent patent expiry with moderate competitive pressure (25th percentile); brand teams will transition from growth optimization to LOE mitigation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on ACTOPLUS MET XR at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.